$30 Million In New Funding Signals "Better Day to Cure Cancer" for Incyclix | North Carolina Biotechnology Center
Newly minted RTP cancer therapeutics developer Incyclix Bio has just received $30 million in Series B financing.
North Carolina United States University Of North Carolina Chapel Hill Research Triangle Park John Bisi
Source: ncbiotech.org